Genome Editing in CAR-T Cells Using CRISPR/Cas9 Technology

Area of Science:

• Immunotherapy
• Molecular Biology
• Cancer Research

Background:

• Chimeric antigen receptor T-cell (CAR-T) therapy shows promise for hematologic malignancies but faces challenges in solid tumors and T-cell cancers.
• Next-generation CAR-T cells require genetic modifications to overcome current therapeutic limitations.

Purpose of the Study:

• To describe a detailed protocol for gene knockout in CAR-T cells using CRISPR-Cas9 technology.
• To enhance CAR-T cell efficacy and accessibility for broader cancer treatment applications.

Main Methods:

• Utilized CRISPR-Cas9 genome editing technology for gene knockout in CAR-T cells.
• Focused on electroporation of ribonucleoprotein complexes (Cas9 protein and sgRNA) for simplicity, versatility, and reduced toxicity.
• Developed protocols for knockout strategy design, CAR-T cell expansion, genome editing, and efficiency analysis.

Main Results:

• Established a robust protocol for targeted gene knockout in CAR-T cells.
• Demonstrated the feasibility of enhancing CAR-T cell function through genetic modification via CRISPR-Cas9.
• Validated the efficiency of the electroporation method for CAR-T cell genome editing.

Conclusions:

• CRISPR-Cas9 technology, particularly via ribonucleoprotein electroporation, offers a viable strategy for engineering advanced CAR-T cells.
• This protocol facilitates the development of more effective CAR-T cell therapies for various cancers, including solid tumors and T-cell malignancies.
• The described methods support the design and analysis of CAR-T cell gene editing strategies to improve therapeutic outcomes.